Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants

Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants

Abstract The recent emergence of multiple SARS‐CoV‐2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS‐CoV‐2 variants....

Full description

Bibliographic Details
Main Authors: Vanessa Monteil, Brett Eaton, Elena Postnikova, Michael Murphy, Benedict Braunsfeld, Ian Crozier, Franz Kricek, Janine Niederhöfer, Alice Schwarzböck, Helene Breid, Stephanie Devignot, Jonas Klingström, Charlotte Thålin, Max J Kellner, Wanda Christ, Sebastian Havervall, Stefan Mereiter, Sylvia Knapp, Anna Sanchez Jimenez, Agnes Bugajska‐Schretter, Alexander Dohnal, Christine Ruf, Romana Gugenberger, Astrid Hagelkruys, Nuria Montserrat, Ivona Kozieradzki, Omar Hasan Ali, Johannes Stadlmann, Michael R Holbrook, Connie Schmaljohn, Chris Oostenbrink, Robert H Shoemaker, Ali Mirazimi, Gerald Wirnsberger, Josef M Penninger
Format: Article
Language:English
Published: Springer Nature 2022-07-01
Series:EMBO Molecular Medicine
Subjects:
COVID‐19
treatment
clinical trial
vaccine
Online Access:https://doi.org/10.15252/emmm.202115230

Internet

https://doi.org/10.15252/emmm.202115230

Similar Items